Aussies are some of the most enthusiastic adopters of new clinical drugs. In 2019, 95,000 of us participated in nearly 2,000 clinical trials where Australia is home to many of the world’s leading scientists. In keeping with that, clinical stage biotech company Pharmaxis (ASX: PXS) has a thriving drug development pipeline set to report clinical
Read More
The skin is one of the most overlooked, complex and essential organs. It is the body’s first line of defence against dehydration, infection, and injury and plays a role in thermoregulation, vitamin D absorption and the nervous system. Throughout the course of life we are bound to end up with scars from adventures and mishaps,
Read More
In the wake of their oversubscribed capital raising effort, clinical stage pharmaceutical company Pharmaxis (ASX: PXS) is forging ahead with research into their anti-fibrotic drug pipeline. For those unfamiliar with their work, Pharmaxis is developing drugs based on their proprietary amine-oxidase technology. These drugs work by inhibiting an enzyme pathway that is key in the
Read More